DK0697886T3 - Nye peptidantagonister for glutamat- og NMDA-receptorer - Google Patents
Nye peptidantagonister for glutamat- og NMDA-receptorerInfo
- Publication number
- DK0697886T3 DK0697886T3 DK94916460T DK94916460T DK0697886T3 DK 0697886 T3 DK0697886 T3 DK 0697886T3 DK 94916460 T DK94916460 T DK 94916460T DK 94916460 T DK94916460 T DK 94916460T DK 0697886 T3 DK0697886 T3 DK 0697886T3
- Authority
- DK
- Denmark
- Prior art keywords
- glutamate
- peptide antagonists
- nmda receptors
- novel peptide
- nmda
- Prior art date
Links
- 102000018899 Glutamate Receptors Human genes 0.000 title abstract 4
- 108010027915 Glutamate Receptors Proteins 0.000 title abstract 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000004498 neuroglial cell Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE19939301667A SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | New use |
| PCT/SE1994/000454 WO1994026301A1 (en) | 1993-05-14 | 1994-05-16 | New peptide antagonists at glutamate and nmda receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0697886T3 true DK0697886T3 (da) | 2003-10-20 |
Family
ID=20389945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94916460T DK0697886T3 (da) | 1993-05-14 | 1994-05-16 | Nye peptidantagonister for glutamat- og NMDA-receptorer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US5804550A (xx) |
| EP (1) | EP0697886B1 (xx) |
| JP (1) | JP3819932B2 (xx) |
| AT (1) | ATE247481T1 (xx) |
| AU (1) | AU685123B2 (xx) |
| CA (1) | CA2162924C (xx) |
| DE (1) | DE69433058T2 (xx) |
| DK (1) | DK0697886T3 (xx) |
| ES (1) | ES2204916T3 (xx) |
| NZ (1) | NZ266559A (xx) |
| SE (1) | SE9301667D0 (xx) |
| WO (1) | WO1994026301A1 (xx) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6812208B2 (en) | 1993-12-23 | 2004-11-02 | Neuronz Ltd. | Methods to improve neural outcome |
| CA2178711A1 (en) * | 1993-12-23 | 1995-06-29 | Peter David Gluckman | Composition and methods to improve neural outcome |
| GB9611584D0 (en) * | 1996-06-04 | 1996-08-07 | Univ Edinburgh | Neurotransmitters |
| US7041314B2 (en) | 2001-05-24 | 2006-05-09 | Neuren Pharmaceuticals Ltd. | GPE analogs and peptidominetics |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
| US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| AU2003218460A1 (en) * | 2002-04-05 | 2003-10-27 | Neuronz Biosciences, Inc. | Compositions and methods for immunomodulation |
| US20060128615A1 (en) * | 2002-09-18 | 2006-06-15 | Pierrette Gaudreau | Ghrh analogues |
| EP1529533A1 (en) * | 2003-11-06 | 2005-05-11 | Sahltech I Göteborg AB | Use of GH secretagogues in hypoxic-ischemic brain injury |
| KR101769999B1 (ko) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| CN102933226A (zh) | 2010-02-11 | 2013-02-13 | 西北大学 | 二级结构稳定化的nmda受体调节剂及其用途 |
| WO2014120786A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2014120784A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9738650B2 (en) | 2013-01-29 | 2017-08-22 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CN105308049A (zh) | 2013-01-29 | 2016-02-03 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| SI2951183T1 (sl) | 2013-01-29 | 2019-07-31 | Aptinyx Inc. | Spiro-laktam NMDA receptorski modulatorji in njihove uporabe |
| WO2017201283A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2017306158B2 (en) | 2016-08-01 | 2021-10-14 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
| WO2018026763A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| JP7032378B2 (ja) | 2016-08-01 | 2022-03-08 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| SG11201900554YA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda modulators and methods of using same |
| MX383650B (es) | 2016-08-01 | 2025-03-14 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos. |
| CN112204031B (zh) | 2018-01-31 | 2024-05-24 | 元羿生物科技(香港)有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5017557A (en) * | 1987-07-24 | 1991-05-21 | Industria Farmaceutica Serono S.P.A. | Treatment of infertility with somatotrophin releasing factor |
| SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| DK0597033T3 (da) * | 1991-08-01 | 1997-06-02 | Genentech Inc | IGF-1 til forbedring af den neurale tilstand |
-
1993
- 1993-05-14 SE SE19939301667A patent/SE9301667D0/xx unknown
-
1994
- 1994-05-16 DK DK94916460T patent/DK0697886T3/da active
- 1994-05-16 AT AT94916460T patent/ATE247481T1/de not_active IP Right Cessation
- 1994-05-16 AU AU68108/94A patent/AU685123B2/en not_active Ceased
- 1994-05-16 EP EP94916460A patent/EP0697886B1/en not_active Expired - Lifetime
- 1994-05-16 NZ NZ266559A patent/NZ266559A/xx unknown
- 1994-05-16 CA CA002162924A patent/CA2162924C/en not_active Expired - Fee Related
- 1994-05-16 WO PCT/SE1994/000454 patent/WO1994026301A1/en not_active Ceased
- 1994-05-16 ES ES94916460T patent/ES2204916T3/es not_active Expired - Lifetime
- 1994-05-16 DE DE69433058T patent/DE69433058T2/de not_active Expired - Fee Related
- 1994-05-16 JP JP52470594A patent/JP3819932B2/ja not_active Expired - Fee Related
-
1995
- 1995-11-09 US US08/549,798 patent/US5804550A/en not_active Expired - Fee Related
-
2002
- 2002-02-26 US US10/087,011 patent/US20020115594A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE247481T1 (de) | 2003-09-15 |
| JP3819932B2 (ja) | 2006-09-13 |
| CA2162924C (en) | 2008-12-30 |
| DE69433058T2 (de) | 2004-06-03 |
| AU685123B2 (en) | 1998-01-15 |
| ES2204916T3 (es) | 2004-05-01 |
| JPH08510214A (ja) | 1996-10-29 |
| EP0697886B1 (en) | 2003-08-20 |
| WO1994026301A1 (en) | 1994-11-24 |
| AU6810894A (en) | 1994-12-12 |
| CA2162924A1 (en) | 1994-11-24 |
| DE69433058D1 (de) | 2003-09-25 |
| NZ266559A (en) | 2000-12-22 |
| US20020115594A1 (en) | 2002-08-22 |
| SE9301667D0 (sv) | 1993-05-14 |
| EP0697886A1 (en) | 1996-02-28 |
| US5804550A (en) | 1998-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0697886T3 (da) | Nye peptidantagonister for glutamat- og NMDA-receptorer | |
| NO960630D0 (no) | Heterocykler anvendelige som neurokinin antagonister | |
| NO944578L (no) | Eksitatoriske aminosyre reseptor antagonister | |
| ES2091877T3 (es) | Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia. | |
| DE69633617D1 (de) | Il-17 receptor | |
| CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
| CL2003002756A1 (es) | Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia. | |
| ATE158580T1 (de) | Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten | |
| DE59601122D1 (de) | N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten | |
| DE122011100032I1 (de) | Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer. | |
| ES2135414T3 (es) | Antagonistas del receptor 5-ht4. | |
| DE69226431D1 (de) | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor | |
| ATE230993T1 (de) | Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält | |
| EA199800376A1 (ru) | Антагонисты рецепторов возбудительной аминокислоты | |
| TR199700834T1 (xx) | 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�. | |
| DE68905845D1 (de) | Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren. | |
| TR200000697T2 (tr) | İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları. | |
| NO953892D0 (no) | Imidazolokinoksalinon-derivater som EAA-antagonister | |
| EA199800380A1 (ru) | Антагонисты рецептора возбуждающих аминокислот | |
| MX9603045A (es) | Antagonistas de los receptores endoteliales. | |
| DE69528817D1 (de) | Peptide und dessen verwendungen gegen psoriasis | |
| ATE274908T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen | |
| SE9304236D0 (sv) | New use | |
| NO981188D0 (no) | 5-HT3-reseptorantagonister for dyskinesi |